Development of a Framework for Enhancing the Transparency, Reproducibility and Communication of the Benefit–Risk Balance of Medicines

A Review of Quantitative Risk–Benefit Methodologies for Assessing Drug Safety and Efficacy—Report of the ISPOR Risk–Benefit Management Working Group

(2010) Jeff J. Guo et al.   VALUE IN HEALTH

—CMR International Institute for Regulatory Science Workshop on Measuring Benefit and Balancing Risk 19–20 June 2008 Washington, DC

(2009) S Walker et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Multiple sclerosis patients—benefit-risk preferences: Serious adverse event risks versus treatment efficacy

(2009) F. Reed Johnson et al.   JOURNAL OF NEUROLOGY

Safe Drugs and the Cost of Good Intentions

(2009) Hans-Georg Eichler et al.   NEW ENGLAND JOURNAL OF MEDICINE

Using the Incremental Net Benefit Framework for Quantitative Benefit–Risk Analysis in Regulatory Decision-Making—A Case Study of Alosetron in Irritable Bowel Syndrome

(2009) Larry D. Lynd et al.   VALUE IN HEALTH

A Multiattribute Model for Evaluating the Benefit-Risk Profiles of Treatment Alternatives

(2008) James C. Felli et al.   MEDICAL DECISION MAKING

Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma

(2008) Hans-Georg Eichler et al.   NATURE REVIEWS DRUG DISCOVERY